/
Gastroenterology
Celiac Disease
12
Pipeline Programs↗
16
Active Trials↗
14
Companies Involved↗
Celiac Disease is an emerging landscape with 12 programs across 14 companies. The most active players are Forte Biosciences, Inc., Teva, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
10 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
69
clinical trials
Completed42 · 61%
Recruiting8 · 12%
Unknown status6 · 9%
Not yet recruiting4 · 6%
Terminated4 · 6%
Active, not recruiting3 · 4%
Other2 · 3%
Clinical Trials
Trial Activity
69 trials
A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
Recruiting·—·Phase 1·NCT07377565·20 enrolled
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
Active, not recruiting·—·Phase 2·NCT07298343·356 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)